{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sun L"],"funding":["Natural Science Foundation of Tianjin Municipal Science and Technology Commission","National Natural Science Foundation of China","Tianjin Research Innovation Project for Postgraduate Students for support"],"pagination":["e2104051"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8787384"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["Toll-like receptor (TLR) activation in macrophages plays a critical role in the pathogenesis of acute lung injury (ALI). While TLR inhibition is a promising strategy to control the overwhelming inflammation in ALI, there still lacks effective TLR inhibitors for clinical uses to date. A unique class of peptide-coated gold nanoparticles (GNPs) is previously discovered, which effectively inhibited TLR signaling and protected mice from lipopolysaccharide (LPS)-induced ALI. To fast translate such a discovery into potential clinical applicable nanotherapeutics, herein an elegant strategy of \"nano-enabled drug repurposing\" with \"nano-targeting\" is introduced to empower the existing drugs for new uses. Combining transcriptome sequencing with Connectivity Map analysis, it is identified that the pro"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Nano-Enabled Reposition of Proton Pump Inhibitors for TLR Inhibition: Toward A New Targeted Nanotherapy for Acute Lung Injury."],"pmcid":["PMC8787384"],"funding_grant_id":["81971549","81770070","20JCYBJC00040","2020YJSB136"],"pubmed_authors":["Sun L","Liu X","Yang H","Liu Y","Ma A","Wang R","Fung SY","Saferali A","Ma H","Gao W","Gong J","Turvey SE"],"additional_accession":[]},"is_claimable":false,"name":"Nano-Enabled Reposition of Proton Pump Inhibitors for TLR Inhibition: Toward A New Targeted Nanotherapy for Acute Lung Injury.","description":"Toll-like receptor (TLR) activation in macrophages plays a critical role in the pathogenesis of acute lung injury (ALI). While TLR inhibition is a promising strategy to control the overwhelming inflammation in ALI, there still lacks effective TLR inhibitors for clinical uses to date. A unique class of peptide-coated gold nanoparticles (GNPs) is previously discovered, which effectively inhibited TLR signaling and protected mice from lipopolysaccharide (LPS)-induced ALI. To fast translate such a discovery into potential clinical applicable nanotherapeutics, herein an elegant strategy of \"nano-enabled drug repurposing\" with \"nano-targeting\" is introduced to empower the existing drugs for new uses. Combining transcriptome sequencing with Connectivity Map analysis, it is identified that the pro","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-05-09T04:28:56.372Z","creation":"2022-02-11T15:46:41.64Z"},"accession":"S-EPMC8787384","cross_references":{"pubmed":["34816630"],"doi":["10.1002/advs.202104051"]}}